Research unveils the significance of uridine as a metabolic fuel in pancreatic ductal adenocarcinoma (PDA) cells under glucose-deprived conditions. Uridine utilization, mediated by uridine phosphorylase 1 (UPP1), supports redox balance, survival, and proliferation in PDA, highlighting its potential as a novel therapeutic target in the treatment of this resistant cancer.